Drawing for CELL DYNAMICS

USPTO serial 88792326

CELL DYNAMICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
GOLDEN, LAURA DAWN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CELL DYNAMICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, namely, Intravenous (IV) medications for the treatment of amino acid disorders, ascorbic acid disorders, glutathione disorders, and B vitamins deficiencies; IV medications for the treatment of migraines, diarrhea or constipation, dizziness, vomiting, nausea formulated for delivery via a saline solutions; IV nutritional therapy medicine for the treatment of nutrient deficiencies and dehydration; chemotherapy drugs such as doxorubicin, vincristine, cisplatin, and paclitaxel; antibiotics such as vancomycin, meropenem, and gentamicin; antifungal drugs such as micafungin and amphotericin; pain medications such as hydromorphone and morphine; pharmaceutical preparations for low blood pressure such as dopamine, epinephrine, norepinephrine, and dobutamine; immunoglobulin medications (IVIG) for the treatment of primary immune deficiencies such as multifocal motor neuropathy, chronic lymphocytic lymphoma, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease and immune thrombocytopenic purpura (ITP); topical preparations for the Treatment for medical treatment of Rosacea; Antibiotics; burn solution, namely, preparations for the treatment of burns; pharmaceutical preparations for the treatment of acne, namely, retinoids, metronidazole gel, Erythromycin, Clindamycin topical, Tetracycline, Minocycline topical agents; anorectal preparations, namely, pharmaceutical preparations for the treatment of internal or external hemorrhoids; antiseptics and germicides; dermatological agents; miscellaneous medicated topical agents, namely, topical acne agents, topical anesthetics, topical anti-infectives, topical anti-rosacea agents, topical antibiotics, topical antifungals, topical antihistamines, topical anti-neoplastics, topical antipsoriatics, topical antivirals; topical astringents, topical debriding agents, topical depigmenting agents, topical emollients, topical keratolytics, topical non-steroidal anti-inflammatories, topical photochemotherapeutics, topical rubefacient, topical steroids, topical steroids with anti-infectives; pharmaceutical preparations for the treatment of mouth sores and sore throats; nasal spray preparations; nasal antihistamines and decongestants; nasal lubricants and saline solution for nasal irrigations; nasal steroids; ophthalmic preparations; anti- angiogenic ophthalmic agents; ophthalmic preparations, namely, mydriatics, ophthalmic anesthetics, ophthalmic anti-infectives, ophthalmic anti-inflammatory agents, ophthalmic antihistamines and decongestants, ophthalmic diagnostic agents, ophthalmic glaucoma agents, ophthalmic lubricants and irrigation solutions, ophthalmic steroids, ophthalmic steroids with anti-infectives, ophthalmic preparations for use in surgery, otic preparations, cerumenolytics, miscellaneous otic agents, otic anesthetics, otic anti-infectives, otic steroids, otic steroids with anti-infectives; sterile irrigating solutions, namely, douching preparations for medical purposes; vaginal preparations, namely, antifungals; vaginal washes for medical purposes; spermicides, vaginal anti-infectivesACTIVE—
010Medical supplies, namely, IV administration sets and secondary IV administration sets, comprised of intravenous bags sold empty and catheters; blood administration sets comprised of intravenous bags sold empty and catheters; IV accessories namely, IV manifolds, extension sets, infusion pumps, and IV poles; Apparatus for blood analysis, namely, blood gas analyzers, chemistry analyzers, electrolyte analyzers, drug testing analyzers, coagulation analyzers, hematology analyzers; blood collection supplies, namely, blood drawing apparatus; flow-based analyzers providing cell counting for medical, clinical, medical diagnostic, and therapeutic uses, namely, differential counters; apparatus for urine analysis, namely, urinalysis analyzers; microbiological systems; medical gloves; sterilizing preparationsACTIVE—
042Medical laboratory services; laboratory services, namely, imaging core lab services, namely, quantitative 3D imaging labACTIVE—
044Medical and veterinary services, namely, diagnostic care, substance abuse treatment, preventative care, physical and occupational therapy, nutritional support, pharmaceutical care, men's health, women's health, weight management, IV nutritional therapy service, lifestyle medicine, comprehensive health program, digestive diseases/gastroenterology servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 11, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 10, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 10, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 8, 2022EX3GSOU EXTENSION 3 GRANTED—
Mar 8, 2022EXT3SOU EXTENSION 3 FILED—
Mar 8, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 8, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 8, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 8, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 3, 2022WOAGWITHDRAWAL OF ATTORNEY GRANTED—
Mar 3, 2022WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Mar 2, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 2, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 2, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 10, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 8, 2021EX2GSOU EXTENSION 2 GRANTED—
Sep 8, 2021EXT2SOU EXTENSION 2 FILED—
Sep 8, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 4, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 2, 2021EX1GSOU EXTENSION 1 GRANTED—
Mar 2, 2021EXT1SOU EXTENSION 1 FILED—
Mar 2, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 8, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 14, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 14, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 24, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 8, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 8, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Jun 8, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 8, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 8, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 8, 2020ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jun 2, 2020PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
May 15, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 15, 2020XAECEXAMINER'S AMENDMENT ENTERED—
May 15, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 15, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
May 15, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
May 14, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 14, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 14, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 7, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2020DOCKASSIGNED TO EXAMINER—
Feb 15, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 14, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 14, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance